Brief: Spero Therapeutics Announces First Patient, First Visit For Phase 3 Trial Evaluating Tebipenem HBR
02/01/2024 13:13
Jan 2 (Reuters) - Spero Therapeutics Inc SPRO.O :
* SPERO THERAPEUTICS ANNOUNCES FIRST PATIENT, FIRST VISIT
FOR
PHASE 3 PIVOT-PO TRIAL EVALUATING TEBIPENEM HBR IN COMPLICATED
URINARY TRACT INFECTIONS
* TO RECEIVE $95 MILLION IN DEVELOPMENT MILESTONE PAYMENTS
FROM
GSK, WHICH IS PAYABLE IN FOUR EQUAL INSTALLMENTS OVER TWO YEARS
Source text for Eikon: ID:nGNX282hws
Further company coverage: SPRO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Spero Therapeutics
See all newsBrief: Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Brief: Spero Therapeutics - May Offer Up To $300 Million In Securities - SEC Filing
Brief: Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., As Chief Medical Officer
Spero licenses Innovent's experimental immune disease drug for up to $1.1 billion
US FDA approves GSK's oral antibiotic for drug-resistant UTIs (updated)